Table 4 Outcomes of prophylactic micafungin vs. posaconazole during first induction chemotherapy in newly diagnosed AML patients
From: Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy
| Â | Micafungin, n (%) | Posaconazole, n (%) | P-value |
|---|---|---|---|
Incidence of fungal infection | 2/32 (6.3) | 2/39 (5.1) | 1.000 |
 Proven fungal infection | 1/32 (3.1) | 0 |  |
 Probable fungal infection | 0 | 2/39 (5.1) |  |
 Possible fungal infection | 1/32 (3.1) | 0 |  |
Discontinuation of prophylactic antifungal agent | 17/32 (53.1) | 20/39 (51.3) | 0.877 |
Cause of discontinuation | |||
 Suspected fungal infection | 2/32 (6.3) | 2/39 (5.1) |  |
 Prolonged neutropenic fever | 13/32 (40.6) | 17/39 (43.6) |  |
 Any adverse event | 2/32 (6.3) | 0 |  |
 Oral mucositis | 0 | 1/39 (2.6) |  |
 Antifungal treatment completed | 15/32 (46.9) | 19/39 (48.7) |  |
Change to another antifungal agent | 16/32 (50.0) | 20/39 (51.3) | 0.914 |
Adverse event of prophylactic antifungal agent | 2/32 (6.3) | 4/39 (10.3) | 0.683 |
 Liver function test abnormality | 1/32 (3.1) | 4/39 (10.3) |  |
 Allergic reaction (Grade 2) | 1/32 (3.1) | 0 |  |
 No adverse event | 30/32 (93.8) | 35/39 (89.7) |  |
Cause of mortality during chemotherapy | 3/32 (9.4) | 2/39 (5.1) | 0.652 |
Fungal infection (proven) | 1/32 (3.1) | 0 | Â |
Respiratory failure (pneumonia, pulmonary edema) | 1/32 (3.1) | 1/39 (2.6) | Â |
Septic shock | 1/32 (3.1) | 1/39 (2.6) | Â |